All news articles for February 2019

(Image: Getty/Phototechno)

How to solve a problem like Kymriah

By Ben Hargreaves

In its full-year financials, Novartis announced plans to transform its cell therapy manufacturing process through greater investment and utilisation of digital technologies.

(Image: Getty/Bong Hyunjung)

MedImmune will cease to exist after 30 years

By Ben Hargreaves

In full-year financials, AstraZeneca announced that its R&D arm, MedImmune, will be absorbed into the overall company as it restructures its R&D units into specific therapy areas.

(Image: Getty/Gajus)

Hired and Retired: Pharma C-suites see new faces

By Maggie Lynch

While last month saw many pharma executives leaving their positions to head towards smaller biotech companies, this month saw members of the industry climbing the ladder from various different starting points.

(Image: Getty/wildpixel)

CAR-T for solid tumors drives industry to innovate

By Maggie Lynch

ICT is developing upon CAR-T cell technology to enable T-cells to persist against cancer’s attempt to program death into a patient’s defensive T-cells, which could potentially treat solid tumors.